<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) frequently fail chemotherapy due to refractory disease, relapse, or toxicity </plain></SENT>
<SENT sid="1" pm="."><plain>Among older <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients (age &gt; 60 years), there are few long-term survivors </plain></SENT>
<SENT sid="2" pm="."><plain>Lenalidomide is a candidate for study in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> based on its clinical activity in a related disorder, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), with the 5q- chromosomal abnormality </plain></SENT>
<SENT sid="3" pm="."><plain>We report induction of sustained morphologic and cytogenetic complete remission in 2 older <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated with high-dose, single-agent lenalidomide; each patient had <z:mp ids='MP_0004027'>trisomy</z:mp> 13 as the sole cytogenetic abnormality </plain></SENT>
<SENT sid="4" pm="."><plain>We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897 </plain></SENT>
</text></document>